A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Liviniti Partners with Mindera Health to Improve Psoriasis Patient Care and Reduce Specialty Pharmacy Spend

Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies

Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis patients. The program utilizes Mind.Px™, a dermal biomarker patch, to improve clinical outcomes while reducing biologic drug costs for self-funded employers.

“Inflammatory conditions are a major cost trend driver in the specialty pharmacy space,” says LeAnn Boyd, Liviniti CEO. “Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members.”

Mind.Px predicts the appropriate biologic drug class for an individual patient prior to treatment. It allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians, with >92% positive predictive values. By matching the patient to the right drug class before treatment begins, potential cost savings can be substantial.

“We are delighted to partner with a pharmacy benefit manager like Liviniti to introduce precision medicine to psoriasis patients,” says Ron Rocca, President and CEO of Mindera Health. “We share core values to bring innovation to significant markets to decrease drug costs while improving patient outcomes.”

In the United States, psoriasis affects more than 3% of the population, leading to healthcare costs of more than $110B annually. Specialty drug spend for psoriasis is escalating, and biologics are often identified by payers as one of their top drug expenditures each year. Successful patient responses to currently available biologic treatments are approximately 52%, leading to trial-and-error and increased costs to get patients on the most effective treatment

SourceLiviniti
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy